12.11.25 -- ADCs: Advancements And Insights

The right CRO acts as an accelerator, while the wrong one can slow progress and jeopardize outcomes. But when every provider promises speed and credibility, how can you choose?

Essential for studying therapeutic efficacy and drug resistance mechanisms, explore a validated preclinical model for non-small cell lung cancer that features KRAS mutation and TP53 inactivation.

A successful large-scale public health emergency response requires adaptable manufacturing capabilities, an experienced workforce, and effective private-public partnerships.

Regarding the U.S. / E.U. “agreement” to a blanket 15% tariff on pharmaceuticals entering the former from the latter, a 2025 analysis indicates 43% of branded APIs used in U.S. prescriptions come from the E.U. Learn more about our predicament from a case study and closer look.

Uncover how thermal shift fluorimetry (thermofluor) can be used as a rapid, low-volume, and cost-effective technique to accelerate buffer optimization and enhance protein stability.

As timelines tighten and regulatory demands grow, discover how a European CDMO delivers integrated solutions from aseptic fill and finish to packaging and release.

Review a semi-automated method for dynamically assessing plunger migration under controlled variations in temperature and pressure, utilizing computer vision tools.

Here, a biotech mitigated technical risk, implemented parallel process development, and designed custom purification strategies for highly sensitive novel modalities to accelerate to cGMP material.

Ensure the safety and efficacy of your biotherapeutic by partnering with an experienced CDMO in protein variant characterization, CQA analytics, and patient-centric product development.

Consider a comprehensive strategy for linker-payload design, synthesis, and manufacturing that utilizes a toolbox approach and a specialized bioconjugation team.

A standardized, end-to-end, multi-plant biomanufacturing model enables faster timelines, greater flexibility, and consistent global quality, turning CDMO partnerships into a competitive advantage.

In this update, you will hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support manufacturing programs from clinical through commercial.

Utilizing robust analytical services at every stage of development and manufacturing is crucial to ensure your therapy reaches patients in need on time and within budget.

By transitioning from a 4-plasmid transient system to 1- or 0-plasmid configurations, the LV Edge systems reduce or eliminate the need for GMP plasmids, lowering costs and supply chain risks.

Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network.

Enable an optimized process for mAb development and manufacturing, efficiency, and speed with exceptional quality, and high titers with lower-cost workflows for maximum ROI.